KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial.

Heidi S Harvie, Shawn A Menefee, Holly E Richter, Vivian W Sung, Christopher J Chermansky, David D Rahn, Cindy L Amundsen, Lily A Arya, Evan Rhodes, Donna Mazloomdoost, Sonia Thomas, National Institute of Child Health and Human Development Pelvic Floor Disorders Network

JAMA 333(21) 1887-1896

PMID40323617
PMCIDPMC12053799
DOI10.1001/jama.2025.4682
发表日期2025-05-05
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。
摘要

摘要

IMPORTANCE: Mixed urinary incontinence, which includes both stress and urgency urinary incontinence, adversely affects quality of life and can be difficult to manage. Studies comparing procedural-based treatments for mixed urinary incontinence are lacking. OBJECTIVE: To determine whether intradetrusor onabotulinumtoxinA is more effective than midurethral sling for the treatment of mixed urinary incontinence in females. DESIGN, SETTING, AND PARTICIPANTS: Randomized, superiority trial involving females (aged ≥21 years) with moderate to severe bother from both stress and urgency urinary incontinence who had unsuccessful conservative treatments and oral medications. The study was conducted at 7 US sites with enrollment between July 2020 and September 2022; the last date of follow-up was December 29, 2023. INTERVENTIONS: Intradetrusor injection of onabotulinumtoxinA, 100 U (treatment focused on the urgency component), vs surgical synthetic mesh midurethral sling (treatment focused on the stress component). Recipients of onabotulinumtoxinA could receive an additional injection between 3 and 6 months. All participants could receive additional treatment (including crossover to the alternative treatment) between 6 and 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was change at 6 months in mixed incontinence symptoms as measured by the Urogenital Distress Inventory (UDI) total score (0-300 points; higher scores indicate worse symptoms; minimal clinically important difference, 26.1). Secondary outcomes included stress and irritative UDI subscores. RESULTS: Among 150 females randomized, 137 were treated, had postbaseline outcome data, and were included in the primary analysis (mean [SD] age, 59.0 [11.5] years). Both groups demonstrated mean improvement in UDI total score at 6 months with no significant difference between groups (onabotulinumtoxinA: -66.8 points [95% CI, -84.9 to -48.8]; sling: -84.9 [95% CI, -100.5 to -69.3]; mean difference, 18.1 points [95% CI, -4.6 to 40.7]; P = .12). For secondary outcomes, greater UDI stress score improvement was seen with the sling (-45.2 [95% CI, -53.7 to -36.8]) compared with onabotulinumtoxinA (-25.1 [95% CI, -34.1 to -16.1]) (P < .001); however, no significant difference was seen between groups in UDI irritative score (onabotulinumtoxinA: -32.9 [95% CI, -40.3 to -25.6] vs sling: -27.4 [95% CI, -34.6 to -20.3]; P = .27). In the onabotulinumtoxinA group, 12.7% and 28.2% received a second injection by 6 and 12 months, respectively. By 12 months, 30.3% in the sling group received onabotulinumtoxinA, and 15.5% in the onabotulinumtoxinA group received a sling. Overall, adverse events were not different between groups. CONCLUSIONS AND RELEVANCE: There was no observed difference in UDI total score improvement at 6 months between the onabotulinumtoxinA and midurethral sling groups in females with moderate to severe mixed urinary incontinence who previously did not respond to conservative treatments. These findings may help inform treatment decisions based on patient preference in partnership with clinician recommendations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04171531.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Participant Flow in the Treatment for Mixed Urinary Incontinence: Midurethral Sling vs Botox A Trial SUI indicates stress urinary incontinence; UUI, urgency urinary incontinence. a Specific inclusion and exclusion criteria were not maintained for screening failures. b Randomization was stratified by clinical site and age category (≥65, <65 years). c OnabotulinumtoxinA is focused on treating UUI, and midurethral sling is focused on treating SUI. d One patient was randomized to midurethral sling but received onabotulinumtoxinA. This patient remained in the primary analysis population under midurethral sling, the treatment to which the patient was randomized. e Completion indicates that the patient finished their final follow-up visit. One patient, randomized before the 12-month follow-up extension was added as a protocol amendment, was considered to have completed the study at 6 months. f Treated and had postbaseline efficacy data.
非 KM Figure
Figure 2Figure 2.. Urogenital Distress Inventory (UDI) Total, Irritative, and Stress Scores Change From Baseline UDI total score (range, 0-300), irritative subscale (range, 0-100), and stress subscale (range, 0-100) parallel line plot of observed change from baseline at 6 months by the baseline value, box plots, and model-estimated mean change from baseline at each time point. The minimal clinically important difference is 26.1 for the total score, 10.2 for the irritative subscale, and 5.4 for the stress subscale. Boxplot midlines represent the median value, box ends represent quartile ranges, whiskers represent upper and lower limits at 1.5 times the IQR, and dots not on the lines indicate extreme values. Colored points represent model-estimated mean values.
非 KM Figure